The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Poll|January 18, 2021
Rheumatoid Arthritis Quiz: Biologics
Author(s)Ingrid Torjesen
A range of biologic therapies are available as options for treating patients with rheumatoid arthritis who do not respond to first-line conventional DMARDs, but which to choose and why? Test your knowledge of biologics with this quiz.
Advertisement
Is the following statement True or False?
Biologics are generally more effective than conventional first line treatment for early RA in treatment-naïve patients.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement